Fred Hutch Cancer Center scientists have developed an experimental strategy to give genetically engineered CAR T cells help they'd normally find within lymph nodes — but on the go, within the tumor.

T cell lymphomas are notoriously difficult to treat because immunotherapy, despite being one of the most effective therapies for treating cancer, can't easily distinguish cancerous T cells from ...

CD7 is an attractive target for chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory T-cell acute lymphoblastic leukemia (ALL). Supportive results of first-in-human studies of base ...

A naturally occurring byproduct of liver metabolism—the ketone body, β-hydroxybutyrate (BHB)—can strengthen the fitness and antitumor activity of CAR T cells. The findings, reported on March 6, 2026 ...

Researchers discovered a way to keep T cells from wearing out during the fight against cancer, and the approach could make immune-based treatments far more powerful. They found that tumors use a ...

Our immune system relies on T cells to fight infections. But T cells don't just show up and react—first, they train, get a ...

Phase II Trial of Nivolumab Plus Doxorubicin, Vinblastine, Dacarbazine as Frontline Therapy in Older Adults With Hodgkin Lymphoma Colorectal cancer (CRC) remains a major global health burden, being ...

Killer immune cells destroy cancer cells and cells infected by virus. These CD8 + T cells are activated after detection of viral infection or growth of “non-self” tumor cells. However, in chronic ...

Please provide your email address to receive an email when new articles are posted on . A “complete eradication” of B cells with chimeric antigen receptor T-cell therapy is responsible for the ...

Just before the pandemic took center stage in 2020, scientists at a T cell memory conference convened to discuss a less than traditional topic: nomenclature. Prior to the event, the workshop ...